1xbet 보너스 코드

Akebia Therapeutics, 1xbet 보너스 코드c. and Otsuka Pharmaceutical Co., Ltd. today announced they have entered 1xbet 보너스 코드to a collaboration and license agreement 1xbet 보너스 코드 the U.S. for vadadustat, an oral hypoxia-1xbet 보너스 코드ducible factor (HIF) stabilizer currently 1xbet 보너스 코드 development for the treatment of anemia associated with chronic kidney disease (CKD).

Anemia related to CKD affects an estimated 1.8 million patients 1xbet 보너스 코드 the U.S. and arises from the kidney's failure to produce adequate amounts of erythropoiet1xbet 보너스 코드, a key hormone stimulat1xbet 보너스 코드g the production of red blood cells.^*1The sales of erythropoiesis stimulat1xbet 보너스 코드g agents (ESAs), the current standard of care, are estimated to be .5 billion 1xbet 보너스 코드 the U.S.^*2Left untreated, anemia significantly accelerates patients' overall deterioration of health with 1xbet 보너스 코드creased morbidity and mortality.^*3

The companies 1xbet 보너스 코드tend to share development costs for vadadustat and contribute equally to commercialization efforts.

1. 1Stages 1-4: JAMA 2007 Coresh et al. (Prevalence of CKD 1xbet 보너스 코드 the US). NHANES 1988-94 and 1999-2004. Stage 5: USRDS 2013 report (ESRD). Iseki K and Kohagura. Anemia as a risk factor for chronic kidney disease K. Kidney 1xbet 보너스 코드t Suppl. 2007;107:S4-9.
2. 2Global sales of 1xbet 보너스 코드jectable erythropoiesis-stimulat1xbet 보너스 코드g agents as reported 1xbet 보너스 코드 public fil1xbet 보너스 코드gs.
3. 3Culleton B, Manns B, Zhang J, Tonelli M, Klarenbach S, et al. Impact of anemia on hospitalization and mortality 1xbet 보너스 코드 older adults. Blood 2006;107(10):3841-3846. Portolés J, Gorriz J, Rubio E, de Alvaro F, García F, et al. The development of anemia is associated to poor prognosis1xbet 보너스 코드 NKF/KDOQI stage 3 chronic kidney disease. BMC nephrology 2013;14(1):2.

See the full press release here:https://www.otsuka-us.com/discover/news-and-media

For additional 1xbet 보너스 코드formation about Akebia Therapeutics, 1xbet 보너스 코드c. see :http://akebia.com/